Resimmune, an anti-CD3ε recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma [PDF]
Resimmune is a second-generation recombinant immunotoxin composed of the catalytic and translocation domains of diphtheria toxin fused to two single chain antibody fragments reactive with the extracellular domain of CD3ε. We gave intravenous infusions of
Arthur E. Frankel +6 more
doaj +4 more sources
Combination treatments with the PKC inhibitor, enzastaurin, enhance the cytotoxicity of the anti-mesothelin immunotoxin, SS1P. [PDF]
Activated protein kinase C (PKC) contributes to tumor survival and proliferation, provoking the development of inhibitory agents as potential cancer therapeutics.
Abid R Mattoo +2 more
doaj +2 more sources
Cloning and Expression of Recombinant Immunotoxin using Diphtheria Toxin and Granulocyte Colony Stimulating Factor (G-CSF) [PDF]
Background: Immunotoxin (IT) is a directed toxin containing two distinct sections (immune and toxin parts) covalently bond using specific chemical or peptide linkers.
Fatemeh Donyapoor +2 more
doaj +1 more source
In vivo solid tumor targeting with recombinant VEGF-diphtheria immunotoxin [PDF]
Objective(s): A variety of signaling molecules have been identified that play a role in angiogenesis, of prime importance, vascular endothelial growth factor (VEGF) and its resceptor (VEGFR), which is highly expressed in most human solid tumors ...
Mohammad Hosseininejad-Chafi +9 more
doaj +3 more sources
Anti-Human Endoglin (hCD105) Immunotoxin—Containing Recombinant Single Chain Ribosome-Inactivating Protein Musarmin 1 [PDF]
Endoglin (CD105) is an accessory component of the TGF-β receptor complex, which is expressed in a number of tissues and over-expressed in the endothelial cells of tumor neovasculature.
Begoña Barriuso +7 more
doaj +2 more sources
Design and evaluation of a peptide‐based immunotoxin for breast cancer therapeutics
Immunotoxins are chimeric proteins comprising a specific cellular targeting domain linked to a cytotoxic factor. Here we describe the design and use of a novel, peptide‐based immunotoxin that can initiate selective cytotoxicity on ErbB2‐positive cells ...
Kelsey J. Weigel +6 more
doaj +2 more sources
Dosing optimization of CCR4 immunotoxin for improved depletion of CCR4+ Treg in nonhuman primates
Recently, we have developed a diphtheria toxin‐based recombinant anti‐human CCR4 immunotoxin for targeting CCR4+ tumors and Tregs. In this study, we further optimized the dosing schedule for improved CCR4+ Treg depletion.
Zhaohui Wang +10 more
doaj +2 more sources
Development of Recombinant Immunotoxins for Hairy Cell Leukemia [PDF]
Hairy cell leukemia (HCL) is an indolent B-cell malignancy with excellent initial response to purine analogs pentostatin or cladribine, but patients are rarely, if ever, cured.
Robert J. Kreitman, Ira Pastan
doaj +3 more sources
Recombinant immunotoxin anti-c-Met/PE38KDEL inhibits proliferation and promotes apoptosis of gastric cancer cells [PDF]
Background Our study aims to evaluate the anti-growth effects of recombinant immunotoxin (IT) anti-c-Met/PE38KDEL on gastric cancer cells, and its mechnisms.
Hua Zhang +6 more
doaj +2 more sources
Generation of Active Immunotoxins Containing Recombinant Restrictocin
Restrictocin, a toxin produced by the fungus Aspergillus restrictus, is a potent inhibitor of eukaryotic protein synthesis. Recombinant restrictocin was made in Escherichia coli and purified to homogeneity in large amounts. The recombinant protein was found to be poorly immunogenic in mice with low toxicity, when injected intraperitoneally.
D, Rathore, J K, Batra
openaire +3 more sources

